Eyepoint to present corporate update at td cowen 45th annual health care conference

– company presentation scheduled on tuesday, march 4 th at 9:10am et – – eyepoint to provide enrollment update for ongoing duravyu™ phase 3 pivotal program in wet amd and additional subgroup analyses from phase 2 verona clinical trial in dme – watertown, mass., feb. 25, 2025 (globe newswire) -- eyepoint pharmaceuticals, inc. (nasdaq: eypt), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that jay s.
COWN Ratings Summary
COWN Quant Ranking